Physician profile
Arvind Jariwala
NPI 1457346439
$2,888.42
in general payments reported to CMS, 2019-2025
33 companies · $203 in 2025
The $203 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $887 · 2020: $136 · 2021: $291 · 2022: $410 · 2023: $379 · 2024: $584 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,165.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $634.55 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $273.25 | 2019-2024 | Evenity, Prolia |
| Lilly USA, LLC | $253.43 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $225.48 | 2021-2025 | Eterna, Freestyle Libre 3, Proclaim |
| Janssen Pharmaceuticals, INC | $196.58 | 2019-2021 | |
| Pfizer INC. | $195.64 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.80 | 2019-2024 | Jardiance |
| Astellas Pharma US INC | $130.67 | 2019-2024 | Veozah, Myrbetriq |
| Daiichi Sankyo INC. | $115.93 | 2019-2024 | Injectafer |
| Amarin Pharma, INC. | $62.47 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $61.22 | 2022-2023 | |
| Glaxosmithkline, LLC. | $57.71 | 2022-2024 | Shingrix, Arexvy |
| Abbvie INC. | $57.14 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $56.70 | 2022 | |
| Sanofi-Aventis U.S. LLC | $53.92 | 2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $32.03 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $31.14 | 2019-2021 | |
| Abiomed | $30.51 | 2025 | |
| Grifols USA, LLC | $29.39 | 2019-2025 | Prolastin-C Liquid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.61 | 2019-2021 | |
| Gilead Sciences, INC. | $21.77 | 2019 | |
| Dexcom, INC. | $21.20 | 2025 | Dexcom G6 Transmitter |
| Eisai INC. | $18.92 | 2024 | |
| Shionogi INC | $17.52 | 2019 | |
| Edwards Lifesciences Corporation | $16.37 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Nestle Healthcare Nutrition INC. | $15.51 | 2021 | |
| Phadia US INC. | $15.44 | 2024 | Immunocap |
| Echosens North America, INC. | $14.91 | 2025 | Fibroscan |
| Lexicon Pharmaceuticals, INC. | $14.84 | 2024 | |
| Clarus Therapeutics INC. | $11.79 | 2021 | |
| Sonex Health, INC. | $11.53 | 2023 | Sx-One Microknife |
| Insightec,INC | $11.27 | 2024 | Exablate |
| Ferring Pharmaceuticals INC. | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Jariwala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.